Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
Short Report: Treatment
Fasting plasma glucose 6–12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis
Article first published online: 19 JUN 2012
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK
Volume 29, Issue 7, pages 933–936, July 2012
How to Cite
Karl, D., Zhou, R., Vlajnic, A. and Riddle, M. (2012), Fasting plasma glucose 6–12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis. Diabetic Medicine, 29: 933–936. doi: 10.1111/j.1464-5491.2012.03640.x
- Issue published online: 19 JUN 2012
- Article first published online: 19 JUN 2012
- Accepted manuscript online: 13 MAR 2012 06:31AM EST
- Accepted 6 March 2012
- 6A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23: 736–742., , , , , .
- 11Sanofi-Aventis. Lantus Versus Humalog Mix as Add-On Therapy in Type 2 Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment. 2001. Trial identifier: NCT01336751. Available at http://clinicaltrials.gov/ct2/show/NCT01336751 Last accessed 11 November 2011.